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Background: Neuromyelitis optica (NMO) is a severe, disabling disease of the central nervous system (CNS)
characterized by the formation of astrocyte-destructive, neutrophil-dominated inflammatory lesions in the spinal
cord and optic nerves. These lesions are initiated by the binding of pathogenic aquaporin 4 (AQP4)-specific
autoantibodies to astrocytes and subsequent complement-mediated lysis of these cells. Typically, these lesions form
in a setting of CNS inflammation, where the blood–brain barrier is open for the entry of antibodies and
complement. However, it remained unclear to which extent pro-inflammatory cytokines and chemokines contribute
to the formation of NMO lesions. To specifically address this question, we injected the cytokines interleukin-1 beta,
tumor necrosis factor alpha, interleukin-6, interferon gamma and the chemokine CXCL2 into the striatum of NMO-
IgG seropositive rats and analyzed the tissue 24 hours later by immunohistochemistry.
Results: All injected cytokines and chemokines led to profound leakage of immunoglobulins into the injected
hemisphere, but only interleukin-1 beta induced the formation of perivascular, neutrophil-infiltrated lesions with
AQP4 loss and complement-mediated astrocyte destruction distant from the needle tract. Treatment of rat brain
endothelial cells with interleukin-1 beta, but not with any other cytokine or chemokine applied at the same
concentration and over the same period of time, caused profound upregulation of granulocyte-recruiting and
supporting molecules. Injection of interleukin-1 beta caused higher numbers of blood vessels with perivascular,
cellular C1q reactivity than any other cytokine tested. Finally, the screening of a large sample of CNS lesions from
NMO and multiple sclerosis patients revealed large numbers of interleukin-1 beta-reactive macrophages/activated
microglial cells in active NMO lesions but not in MS lesions with comparable lesion activity and location.
Conclusions: Our data strongly suggest that interleukin-1 beta released in NMO lesions and interleukin-1 beta-
induced production/accumulation of complement factors (like C1q) facilitate neutrophil entry and BBB breakdown
in the vicinity of NMO lesions, and might thus be an important secondary factor for lesion formation, possibly by
paving the ground for rapid lesion growth and amplified immune cell recruitment to this site.
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Neuromyelitis optica (NMO) is a severe demyelinating in-
flammatory disease of the central nervous system (CNS)
[1]. Diagnostic hallmark of NMO is the presence of patho-
genic autoantibodies against aquaporin 4 (AQP4) [2], a
water channel on astrocytes which is particularly enriched
at the perivascular and subpial glia limitans. We and
others recently showed that these autoantibodies gain
access to their target structures in the course of CNS
inflammation mediated by the action of CNS antigen-
specific T cells [3-5]. In this experimental paradigm, T cells
are needed to open the blood–brain barrier (BBB) for the
entry of antibody and complement. We hypothesized that
also some cytokines and chemokines, which are produced
in the course of brain inflammation, might render the
BBB permeable for the entry of antibodies and comple-
ment. To address this issue, we used Lewis rats as
recipients for intrastriatal injections of cytokines and
chemokines, and peripherally challenged these animals
with pathogenic antibodies against AQP4 or control IgG.
We observed that interleukin-1 beta (IL-1β) was able to
trigger the formation of lesions with AQP4 loss outside
the needle tract, which was associated with breakdown of
the BBB and tissue infiltration by neutrophils. Further-
more, we detected pronounced IL-1β expression in active
lesions of NMO patients, but not in stage-matched lesions
of multiple sclerosis (MS) patients.Figure 1 Blood–brain barrier breakdown induced by the intrastriatal
extravasation of immunoglobulins. (a-l) Cerebral hemispheres from juve
immunoglobulins (brown; a-f) and adjacent sections stained for the presen
injections of 0.3 μl PBS containing 30 ng of IL-1β (a,g), TNF-α (b,h), IFN-γ (c
IgG leakage between the different experimental groups was not significantResults
Cytokine/chemokine-induced leakage of
immunoglobulins across the blood–brain barrier
In first experiments, we injected several different cyto-
kines and chemokines (IL-1β, TNF-α, IFN-γ, CCL7,
CX3CL1, CXCL1, CXCL2, and IL-6) into the striatum of
juvenile Lewis rats, and analyzed the integrity of the
BBB 18–24 hrs later, using rat IgG leakage into the CNS
parenchyma as surrogate marker for barrier dysfunction.
We found that the injection of IL-1β, TNF-α, IFN-γ,
CXCL2, and IL-6 caused profound leakage of rat IgG
(data not shown). These findings raised the question
whether pathogenic serum antibodies against AQP4
could also enter in sufficient concentrations to initiate
damage to astrocytes. To address this point, we next
injected these cytokines into the striatum, and at the
same time provided NMO-IgG (J0) or human control
IgG by intraperitoneal injections as described [4].
18–24 hrs after injections, the brains of these animals
were examined. We found clear evidence for wide-
spread leakage of both rat and human IgG (Figure 1),
which was not only confined to the injected striatum,
but was also seen throughout the entire ipsilateral
hemisphere, affecting cortex, corpus callosum, stri-
atum and thalamus (Figure 1). In all cases, the
contralateral sides did not show any evidence for IgG
leakage (data not shown).injection of cytokines and chemokines, as indicated by the
nile NMO-IgG seropositive Lewis rats stained for the presence of rat
ce of human immunoglobulins (brown; g-l) 20–24 hrs after intrastriatal
,i), CXCL2 (d,j), IL-6 (e,k) or no further additives (f,l). The differences of
. Dashed line: needle tract. Scale bar: 1 mm.
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tract
We then studied the effects of this treatment on AQP4
reactivity within the tissue. Only the area immediately adja-
cent to the needle tract revealed AQP4 loss, but there were
no statistically significant differences in the extent of AQP4
loss between the different treatments indicating that these
pathological changes at the needle tract were rather caused
by the wounding itself than by the action of NMO-IgG at
this site (Figure 2). Since all cytokines/chemokines were
injected at the same concentration, we next made sure that
this concentration was high enough to show biological
activity, i.e. to recruit immune cells to the area around
needle tract. We found that injection of IL-1β and CXCL2
was associated with a significant recruitment of neutrophils,
injection of TNF-α with significant recruitment/activation
of macrophages and microglia, and injection of IFN-γ withFigure 2 Pathological findings at the needle tract. The extent of AQP4
macrophages/activated microglial cells (g-i), and CD3+ T cells (j-l) are prese
derive from the striatum of 3-week old Lewis rats injected with 30 ng of IL
(PBS, veh) as indicated (quantifications). Animals were seropositive for NMO
between individual cytokine treatments are shown (*p<0.05, ANOVA-Duneslight increase in the number of CD3+ Tcells, although this
did not reach significance (Figure 2). Hence, the cytokine/
chemokine concentrations were sufficiently high to reveal
effects. Moreover, the effects of IL-1β and CXCL2 were re-
markably similar in NMO-IgG seropositive and control IgG
positive animals, indicating that, for changes observed at
the needle tract, the action of the cytokines was more
important than the presence of NMO-IgG.Formation of additional, perivascular lesions
Although all the animals described above had compar-
able AQP4-specific antibody titres in their serum (data
not shown), they displayed remarkable differences in the
formation of additional lesions:
After intrastriatal injection of CXCL2 and supplementa-
tion of the immune system with NMO-IgG, 2/9 animalsloss (a-c) and the infiltration of W3/13+ granulocytes (d-f), ED1+
nted. All histological samples and quantitative data (c,f,i,l) shown
-1β (histological data), and of IL-1β, TNF-α, IL-6, IFN-γ, CXCL2, or vehicle
IgG or control IgG as indicated. Statistically significant differences
tt T3). Scale bars: 1 mm (a,d,g,j) and 100 μm (b,e,h,k).
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neutrophil infiltration. It remained unclear whether they
had formed de novo, or whether they represented a con-
tinuum with the actual site of injury, since they were
found in immediate proximity to the needle tract.
However, after intrastriatal injection of IL-1β into
NMO-IgG seropositive animals, 3/5 juvenile and 3/5 adult
rats showed small perivascular lesions with neutrophilic
infiltrates and AQP4 loss, which developed clearly inde-
pendently from the needle tract-associated area of AQP4
loss (as revealed by careful analysis of consecutive tissue
sections). The frequency of these neutrophil-infiltrated
lesions with AQP4 loss was highly variable, ranging from
1–8 per lesion-positive rat (Figure 3), which might explain
why we also had some animals in each group where we
could not detect them at all. In general, these lesions were
scattered throughout the entire ipsilateral hemisphere,
and were found in the cortex, striatum and thalamus
(Figure 3, Additional file 1), but not in the corpus
callosum, possibly due to the fact that AQP4 expression is
higher in gray matter than in white matter. In all these
lesions, the number of CD3+ T cells was extremely low
(on average 12 cells/mm2). Neutrophils (on average 732
cells/mm2) and ED1+ microglia/macrophages (on average
594 cells/mm2) were the dominating cells (Additional
file 1). Complement deposition in these lesions was vari-
able (Additional file 2), correlated well with the loss of
GFAP+ astrocytes or astrocytic foot processes, but was
always less pronounced than the complement deposition
seen at the needle tract.
There was no evidence for the infiltration of eosinophils,
for demyelination or the presence of myelin degradation
products in macrophages within these lesions (data not
shown), which is in line with the fact that eosinophil re-
cruitment is not a feature of NMO-like lesions in Lewis
rats [4], and with the lack of demyelination within a similar
time window in previously published NMO models [3,4].
All the data described above have been obtained with
NMO-IgG derived from one single patient (J 0). To further
substantiate our findings, we repeated these experiments
with intrastriatal injection of IL-1β, and intraperitoneal
application of IgG from 3 additional anti-AQP4 antibody-
positive NMO patients, 2 different anti-AQP4 antibody-
negative NMO patients, 3 anti-AQP4 antibody-negative
MS patients, and from 2 different AQP4 antibody-positive
NMO patients after depletion of AQP4-specific antibodies.
Lesions with AQP4 loss and neutrophil infiltration were
only observed in the presence of anti-AQP4 antibodies of
seropositive NMO patients, but not when AQP4-specific
antibodies had been depleted from the NMO-IgG prepara-
tions, and also not with any other anti-AQP4 antibody-
negative human control IgG (Figure 3).
When IL-1β had been injected into the striatum of
human control IgG seropositive animals, neutrophil-infiltrated lesions with AQP4 loss were absent, but small
blood vessels with large numbers of intraluminal neutro-
phils were observed (Additional file 1).
The effects of IL-1β on endothelial cells of the BBB
Cytokines/chemokines have only short half-life times [7]
and are rapidly redistributed from the parenchyma to
the vasculature [8]. Yet, only IL-1β was able to trigger de
novo formation of perivascular lesions with neutrophilic
infiltration and AQP4 loss distant from the needle tract,
which indicated that the BBB became permeable for
NMO-IgG and complement. To learn more about the
mechanisms involved in this process, we cultured rat
brain microvascular endothelial cells and confronted
these cells for 22 hours with IL-1β, or with other cyto-
kines/chemokines or vehicle as control. We observed
that IL-1β was much more efficient in inducing a strong
upregulation of mRNA for the granulocyte-recruiting
chemokines Cxcl1 and Cxcl2, and for granulocyte colony
stimulating factor Csf-3 than any other molecule tested.
In addition, IL-1β also triggered enhanced expression of
transcripts encoding the monocyte/macrophage-recruiting
chemokines Ccl2 and Ccl5, and the adhesion molecules
ICAM-1 and VCAM-1 (Figure 4, Table 1). All these effects
were identical in endothelial cells derived from juvenile
and adult Lewis rats (Figure 4). The increased production
of Cxcl1 and Ccl2 by IL-1β could be further confirmed at
protein level, using endothelial cell lysates prepared 12
hours after IL-1β treatment (Figure 4), and the expression
of ICAM-1 was confirmed by immunocytochemistry on
IL-1β-treated endothelial cells (Figure 4).
The effects of IL-1β on astrocytes and microglia
We next tested whether IL-1β has also effects on astro-
cytes and microglial cells in vitro. We observed that incu-
bation of astrocytes with IL-1β increased the expression of
Cxcl1, Cxcl2, Ccl2, Ccl5 and VCAM-1, while it had little
effects on the constitutive expression of ICAM-1 in these
cells. In contrast, microglia constitutively expressed Cxcl1,
Cxcl2, Ccl2 and ICAM-1 transcripts, possibly due to the
baseline activation (and IL-1β production) of these cells
under culture conditions. CSF-3 mRNA, however, was
not detected in IL-1β treated astrocytes or microglia
(Additional file 3).
The effects of IL-1β on the local availability of
complement components
As described above, lesions with AQP4 loss and neutro-
phil recruitment showed a variable extent of comple-
ment deposition. Therefore, we studied the effects of
intrastriatal cytokine injections on perivascular C1q re-
activity in NMO-IgG seropositive animals. The largest
number of blood vessels with perivascular C1q+ cells
was observed in animals subjected to IL-1β treatment,
Figure 3 Location and frequency of lesions with AQP4 loss and neutrophil infiltrates outside the needle tract, after intrastriatal
injection of IL-1β and intraperitoneal application of NMO-IgG. The location (red dots in the schemes of [6]; a,b) and histology (c,d) of
perivascular lesions with AQP4 loss and neutrophil infiltration in adult animals seropositive for the NMO-IgGs, J0 (a,c) and I GF (b,d), that received
intrastriatal injection of IL-1β (gray area represents the injection site). Similar lesions were not observed after transfer of IgGs from a NMO-IgG
negative NMO patient (e), or three NMO-IgG negative MS patients (f-h). The number of those lesions was significantly higher in IL-1β/NMO-IgG
injected animals (n=29) than in the controls (n=47), according to Mann Whitney U test with Bonferroni Holm correction (i). The following NMO-
IgG or control IgG preparations were used: NMO-IgG J0 (1, 2, 7-14), NMO- IgG I GF (3, 4), NMO-IgG7 (5) and NMO-IgG8 (6). As controls, IgG
preparations of two AQP4 antibody negative NMO patients (J3 and J4; 15), three NMO-IgG negative MS patients (J5, J6, J7; 16 and 17), and
subcuvia (18, 19) were used. Experiments 1, 3, 7, 9, 11, 12, 13, 15 and 18 were performed using juvenile animals, and experiments 2, 4, 5, 6, 8, 10,
14, 16, 17 and 19 using adult rats. Cytokines were injected as indicated. The AQP4-specific antibodies found in the NMO-IgG preparations are
responsible for the formation of lesions, as revealed by absorption studies using two different NMO-IgG preparations (j-l). Lesions were present
(j, l; white circles) when NMO-IgG had been exposed to emGFP transfected HEK 293 cells, but were absent (k, l; black circles) when NMO-IgG had
been exposed to AQP4-emGFP transfected HEK 293 cells. Bar=25 µm.
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Figure 4 The effects of cytokines and chemokines on rat brain endothelial cells in vitro. Rat brain endothelial cells (EC) were isolated from
the cerebra of 3-week old (a,c) and adult (b,d) Lewis rats, and are shown here in phase-contrast microscopy (a,b) and after staining with an
antibody against zonula occludens 1 (ZO-1, red; c, d; scale bar = 25 μm). (e) Endothelial cells from 3-week old (left panel) and adult (right panel)
Lewis rats were stimulated for 22 hours with vehicle, IL-1β, IL-6, IFN-γ, TNF-α, or CXCL2, and then subjected to PCR analysis of the following
genes: Cxcl1, Cxcl2, Csf3, Ccl2, Ccl5, Icam1, Vcam1, and GAPDH. These data are representative of 2 different, independently performed
experiments. (f,g,h) The lysates of rat brain endothelial cells treated for 12 hours with IL-1β (f) or vehicle (g) were analyzed with antibody arrays
and revealed changes in protein expression of CXCL1 (red rectangle), CXCL3 (gray rectangle) and CCL2 (green rectangle). The fold-change in
signal intensity of these different proteins was then calculated using the Image J software of the National Institute of Health. (i,j) Rat brain
endothelial cells cultured for 24 hours in the presence of IL-1β (i) reveal a marked increase in ICAM1 protein expression (green), which was not
seen after 24 hours of culture in the presence of vehicle (j). All cells were counterstained with antibodies against ZO-1 (red). Bar = 25 μm. Data
are representative of 2 different experiments.
Kitic et al. Acta Neuropathologica Communications 2013, 1:5 Page 7 of 15
http://www.actaneurocomms.org/1/1/5followed by animals injected with TNF-α (Figure 5,
Table 1). After the injection of IFN-γ, IL-6 or CXCL2,
the number of such vessels was similar to PBS-injected
control animals (Figure 5, Table 1).
IL-1β reactivity in active lesions of NMO patients
We analyzed the expression of IL-1β in human NMO le-
sions of different stages in comparison to multiple scler-
osis lesions and controls. In active NMO lesions, which
were characterized by immunoglobulin and complement
deposition (Figure 6), massive granulocyte infiltration
(Figure 6), AQP4 loss and acute astrocyte and tissue in-
jury (data not shown), we found profound expression of
IL-1β in activated macrophages and microglia (Figure 6).
This IL-1β expression was restricted to active lesions,
while no IL-1β immunoreactivity was detected in more
advanced NMO lesions, which lacked complement acti-
vation and granulocyte infiltration (Table 2). Further-
more, IL-1β expression was below the level of detection
in our immunohistochemical staining of active demye-
linating lesions of acute (Figure 6) or chronic MS, or in
control brains (Table 2). These differences in IL-1β ex-
pression were not a feature of lesion sites (in spinal
cords/medullas of NMO patients vs. brains of MSTable 1 Effects of the cytokines on gene expression by rat br
in vivo
Molecules induced in brain endothelial cells in vitro E
Cytokine P
Used Cxcl1 Cxcl2 Csf3 Icam1 Vcam1
IL-1β +++ +++ +++ + +
TNF-α + + - ++ ++
IFN-γ - - - + +
Cxcl2 - - - - -
IL-6 - - - - -
control - - - - -
Semiquantitative analysis of gene expression studies in rat brain endothelial cells is
hemisphere of 3 week-old NMO-IgG seropositive Lewis rats treated with/injected w
revealed strong (+++), intermediate (++), or weak (+) induction of Cxcl1, Cxcl2, Csf3
perivascular granulocytic infiltrates and lesions with AQP4 loss, and by the levels of
requirements for the formation of de novo perivascular lesions with AQP4 loss and
(§ represents 3 small lesions found in the ipsilateral hemisphere of 6 animals. Thesepatients), because IL-1β expression was essentially ab-
sent in initial/active spinal cord and medullary lesions of
MS cases 10 and 11, and in late/active lesions in the
spinal cords and optic chiasm of patients with progres-
sive MS (cases 12–17) (Table 2). Moreover, also in EAE,
lesions in brain and spinal cord essentially show the
same pattern of IL-1β reactivity (data not shown).
Discussion
It is well established that in both NMO patients and
animals with NMO/EAE, binding of pathogenic AQP4-
specific antibodies to astrocytes paves the way for comple-
ment fixation on astrocytes and subsequent destruction
of these cells. Unfortunately, the actual mode of entry
of these antibodies into the CNS is much less clear. In the
healthy CNS, an intact blood–brain barrier seems to
efficiently prevent the entry of anti-AQP4 antibodies into
the parenchyma. This assumption derives from the
observation that NMO patients can be anti-AQP4 antibody
positive for many years prior to the onset of the disease [9],
and that peripherally administered pathogenic AQP4-
specific antibodies do not spontaneously enter the CNS
parenchyma of experimental animals [4,10]. However, in
the inflamed CNS of rats with NMO/EAE, such NMOain endothelial cells in vitro and on tissue pathology
ffects in the injected brain hemisphere in vivo
erivascular granulocytic hIgG perivascular Perivascular lesions
Infiltrates Leakage C1q reactivity With AQP4 loss
++ ++ ++ ++
- ++ + -
- ++ - -
+ ++ - + §
- + - -
- + - -
olated from juvenile and adult Lewis rats, and effects in the ipsilateral brain
ith IL-1β, TNF-α, IFN-γ, Cxcl2, IL-6 or vehicle control (PBS). In vitro effects
, Icam1, and Vcam1. In vivo effects were evaluated by the occurrence of
hIgG and C1q reactivity. Please note that only after treatment with IL-1β, all
granulocyte infiltration are fulfilled.
lesions were in close proximity to the needle tract area).
Figure 5 Perivascular C1q reactivity in the cytokine-injected
hemisphere of animals harboring serum NMO-IgG. Histological
analysis (a-f) of blood vessels with cellular C1q reactivity covering > 50%
of the vessel abluminal surface, which were found after the intrastriatal
injection of IL-1β (a,b) and TNF-α (c,d), but not after injection of vehicle
(PBS, e,f), IFN-γ, IL-6 or CXCL2 (not shown). Consecutive sections were
stained with antibodies against C1q (red, a,c,e) and human IgG (brown,
b,d,f), and counterstained with hematoxylin to reveal nuclei (blue). C1q+
glial cells are indicated by arrows. Scale bars: 25 μm.
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cellular targets, fix and activate the classical complement
cascade [3,4] and trigger the formation of granulocyte-rich,
astrocyte-destructive lesions [3-5,11] similar to what is seen
just after the direct injection of NMO patient-derived
AQP4 specific antibodies and human complement into the
mouse brain [12]. In NMO/EAE, the stage for lesion forma-
tion is set outside the CNS, by activated CNS antigen-
specific T cells, which migrate into the CNS and open the
BBB for the entry of cellular and humoral immune media-
tors at the onset of CNS inflammation. Are there also
conditions where the stage for lesion formation is set inside
the CNS? We reasoned that this might be indeed the case,
and that the local production of IL-1β which is involved in
a broad spectrum of CNS diseases [13], might also contrib-
ute to the initiation and/or propagation of lesions within
the CNS. To specifically address this point, we injected
IL-1β and other cytokines/chemokines with known pro-
inflammatory functions like TNF-α [14], IFN-γ [15], IL-6
[7,16], and CXCL2 into the striatum, and studied the con-
sequences of this treatment for the recruitment of AQP4-
specific antibodies, complement and neutrophils to theCNS. We observed that, in the presence of NMO-IgG in
the serum, intrastriatal injection of IL-1β, TNF-α, IFN-γ,
and CXCL2 lead to widespread leakage of human IgG into
the CNS parenchyma. And yet, only IL-1β caused the
formation of perivascular lesions with granulocytic infiltra-
tion and AQP4 loss distant from the injection site. The
small size of these lesions (in contrast to the highly exten-
sive human NMO lesions) is probably due to a temporally
more restricted opening of the BBB in our model, as was
also observed in other animal models of EAE [4], but could
also demonstrate that additional mechanisms are needed
for the formation of NMO lesions besides the presence
of NMO-IgG, i.e. the recruitment of granulocytes, the
local availability of complement, and sufficient amounts
of activated macrophages. Such conditions, for example,
are provided in the context of T cell-mediated CNS inflam-
mation [4].
Breakdown of the BBB in response to intrastriatal cyto-
kine/chemokine injections has already been described be-
fore [17,18]. It was also observed as a result of intrastriatal
injection of adenoviruses expressing IL-1 [19], and could
be prevented by neutrophil depletion prior to intrastriatal
IL-1β injection [20]. It has also been reported that high
levels of TNF-α cause BBB breakdown [21]. Although
TNF-α was also able to induce a profound leakage of IgG
into the injected hemisphere, we did not see the de novo
formation of perivascular lesions. The most likely explana-
tions for this finding is the fact that IL-1β acts faster and
in much lower concentrations on enthothelial cells than
TNF-α [22], and that IL-1β is much more effective in neu-
trophil recruitment than TNF-α [23]. Granulocytes play
an important role in the formation of NMO lesions, since
the severity of NMO lesions is increased in mice made
neutrophilic, and reduced in mice made neutropenic [24].
IL-1β activates endothelial cells [9,23], which upon IL-
1β stimulation produce a number of key molecules lead-
ing to the recruitment, production, mobilization, and
enhanced survival of neutrophils. Examples of these
molecules are Cxcl1 and Cxcl2, Ccl2 and Ccl5, and Csf3
(see our results above, and [25-28]). With the exception
of Csf3, these proteins are also produced by IL-1β acti-
vated astrocytes [29,30] and microglia [30,31]. They
could diffuse through the parenchyma and accumulate
at the BBB [8], and could further support the recruit-
ment of neutrophils once the BBB is open. Moreover,
IL-1β, TNF-α, and IFN-γ can increase the permeability
of the BBB [32,33], which could lead to the leakage of
complement proteins into the CNS, and they can induce
C1q transcription in microglia [34] and astrocytes [35]. In-
creased parenchymal synthesis of C1q precedes blood–
brain barrier dysfunction [34], C1q can contribute to the
endothelial expression of Vcam1 [36], C1q binding to tar-
get cell-bound NMO-IgG can trigger antibody-dependent
and/or complement mediated cytotoxicity [37,38], and the
Figure 6 IL-1β expression in NMO lesions. IL-1β is expressed in active lesions of NMO patients (a). Perivascular lesions with pronounced IL-1β
expression (b) show the characteristic pattern of complement C9neo deposition (c). IL-1β reactivity was absent in active lesions of acute MS cases
(d,g), which were characterized by a high extent of demyelination (e, Kluever staining) and marked microglia activation (f, shown here by Iba1
immunostaining). No signal in NMO lesions was detected upon application of secondary antibody alone (h). Confocal microscopy shows
macrophages in active NMO lesions stained with IL-1β+ (green, i) and Iba1+ (red, j). An overlay of these two different stainings is shown in
(k). Scale bars: 100 μm (a,d,e,f,h), 50 μm (b,c), 25 μm (g), and 10 μm (i-k).
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cruitment [39]. We observed higher numbers of blood
vessels with perivascular C1q reactivity in NMO-IgG sero-
positive rats after the intrastriatal injection of IL-1β and
TNF-α.
IL-1β was the only cytokine able to both upregulate
neutrophil recruiting/supporting molecules in brain
endothelial cells and complement components in brain
parenchymal cells. Locally produced and serum-derivedcomplement components might then become activated
by NMO-IgG bound to AQP4, and cause NMO lesions.
What could all these findings mean for NMO patients?
We observed that patients with NMO have significantly
more IL-1β expressing macrophages in early active le-
sions than MS patients with stage-matched lesions do.
Although the presence of IL-1β in active MS lesions had
been reported elsewhere [40,41], it was below the
Table 2 Pathological findings in the CNS of NMO and MS patients and controls
Case CNS Granulocyte Complement IL-1β
number diagnosis CNS area Lesion activity infiltration deposition reactivity
1 NMO spinal cord initial/active +++ yes +++
1 NMO spinal cord initial/active +++ yes +++
2 NMO medulla oblongata initial/active + (1 area) yes +++
3 NMO spinal cord initial/active +++ yes ++
1 NMO spinal cord late/active + yes + (astrocytes)
4 NMO medulla oblongata late/active + low ++
3 NMO optic chiasm late/active +++ low ++
1 NMO pons inactive - no -
1 NMO mesencephalon inactive - no -
1 NMO frontal cortex + WM inactive - no -
1 NMO frontal cortex + WM inactive - no -
5 acute MS occipital cortex initial/active - no -
6 acute MS cerebellum + WM initial/active - no -
7 acute MS cortex + WM initial/active - no -
8 acute MS parietal cortex + WM initial/active + no +
9 acute MS parietal cortex + WM initial/active - no -
10 acute MS medulla oblongata initial/active - no +/− (single cells)
10 acute MS spinal cord initial/active - no +/− (single cells)
11 RRMS spinal cord initial/active - no -
12 PMS spinal cord active - no -
13 PMS optic chiasm late/active - no -
14 PMS spinal cord late/active - no -
15 PMS spinal cord late/active - no +/− (microglia)
16 PPMS insular cortex + WM initial/active - no -
17 SPMS periventricular WM + basal ganglia chronic - no -
18 HSE hippocampus - - no +++
19 No CNS pathology cortex + WM - - no -
20 No CNS pathology temporal cortex + WM - - no -
Semiquantative analysis revealing different extents (−, +, +++) of granulocyte infiltration, complement deposition and IL-1β reactivity in inflammatory lesions of
patients with neuromyelitis optica (NMO), acute multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS), secondary progressive MS (SPMS), Herpes
simplex encephalitis (HSE) and control cases without any CNS pathology. WM = white matter.
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able in our laboratory, using well-established immuno-
histochemical methods. On the other hand, the same
immunostaining procedure revealed a high number of
strongly IL-1β -positive microglia (considerably different
from those reported in [40]) in active lesions of NMO
patients (Figure 6), as well as in HSE-affected brain tis-
sue (data not shown). The observed pattern of IL-1β re-
activity in human CNS material was also confirmed at
mRNA level, by in situ hybridization (data not shown).
Moreover, other groups also described elevated levels of
IL-1β or IL-1β/TNF-α induced molecules like IL-1ra, IL-
6, IL-8, IL-13, G-CSF, and Cxcl10 (IP-10) in the CSF of
NMO patients, compared to the CSF of patients with
multiple sclerosis or other neurological diseases [7,42].Enhanced IL-1β expression most likely derives from
the inflammatory condition per se [14,43], where IL-1β
is produced by activated microglia cells/macrophages
and most likely – in much lower concentrations – also
by neutrophils, the most abundant cell type in acute
NMO lesions. Although it was for a long time a matter
of debate, it is now firmly established that neutrophils
do not only transcribe IL-1β mRNA, but are also able to
produce and release this protein, essentially only upon
stimulation by IL-1β itself or TNF-α [44].
There might be additional amplification mechanims:
NMO patients have elevated expression of two key cyto-
kines in their cerebrospinal fluid: IL-6 [7,16] and IL-17
[45]. Both the production of IL-6 by astrocytes, and the
stabilization of IL-6 mRNA are triggered by IL-1β
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mRNA for CXCL1 [48], a molecule induced in endothe-
lial cells by the action of IL-1β. In addition, IL-17
synergizes with TNF-α to cause an enhanced endothelial
expression of neutrophil recruiting chemokines and ad-
hesion molecules [49].
Finally, IL-1β can induce further expression of IL-1β
[50,51], which could provide a powerful amplification
mechanism to drive neuroinflammatory changes in the
brain [13], and it can induce the expression of AQP4 in
astrocytes [52], which could increase the amount of tar-
get molecules for pathogenic NMO-IgG.
Conclusions
All the evidence summarized above strongly suggests
that the IL-1β released in NMO lesions and the IL-
1β-induced local production/accumulation of comple-
ment components might facilitate neutrophil entry and
BBB breakdown in the vicinity of NMO lesions, and
might thus be an important secondary factor for lesion
formation, possibly by paving the ground for rapid lesion
growth and amplified immune cell recruitment to this
site. By doing this, local IL-1β production might play an
important role in the propagation and amplification of
tissue injury in NMO.
Methods
Human CNS samples
Autopsy CNS tissues of patients and control cases archived
at the Center for Brain Research, Medical University of
Vienna, Austria were used. They included 4 cases with
NMO (cases 1–4), 6 cases with acute MS (cases 5–10), 1
case with relapsing remitting MS (case 11), 1 case with pri-
mary progressive MS (case 16), 6 case with secondary pro-
gressive MS (case 12–15, 17), 1 case with herpes simplex
encephalitis (case 18), and 2 cases without evidence of
CNS pathology (cases 19 and 20). Studies on archival aut-
opsy tissue were approved by the Ethics Committee of the
Medical University of Vienna (EK No. 535/2004/2012).
Animals
All Lewis rats used in this study were obtained from
Charles River Wiga (Sulzfeld, Germany). They were housed
in the Decentral Facilities of the Institute for Biomedical
Research (Medical University Vienna) under standardized
conditions. The experiments were approved by the Ethics
Committee of the Medical University Vienna and per-
formed with the license of the Austrian Ministery for
Science and Research.
Injections into the striatum
3-week old (juvenile) and 7-week old (adult) wildtype
Lewis rats were anesthetized with Ketanest S/Rompun
and injected into the striatum as described [53], using0.3 μl solution containing 100 ng/μl of the respective
cytokines and chemokines in sterile endotoxin-free PBS.
The needle was left in place for additional 10 min before
it was removed. Immediately afterwards, some rats were
left untreated, while the others additionally received an in-
traperitoneal injection of patient-derived IgG or control
IgG (10 mg/ml; 0.5 ml injected in juvenile animals, 1 ml
injected in adult animals). The animals were sacrificed
18–24 hrs later for histological analyses.
Sources of cytokines
The following cytokines were used: rat recombinant IL-1β,
IL-6, interferon gamma (IFN-γ), tumor necrosis factor
alpha (TNF-α), chemokine (C-X3-C motif) ligand 1
(Cx3cl1) (all from R&D Systems, Minneapolis, MN, USA),
rat recombinant chemokine (C-C motif) ligand 7 (Ccl7)
and rat recombinant chemokine (C-X-C motif) ligands 1
and 2 (CXCL1 and CXCL2) (all from PreproTech, Rocky
Hill, NJ, USA).
Sources and characterization of patient-derived
immunoglobulin preparations
Unless otherwise indicated, experiments were performed
with the anti-AQP4 antibody containing human NMO-
IgG derived from patient J 0 [4]. We further used human
immunoglobulin preparations from patients I GF [4], J
NMO-IgG6, J NMO-IgG7, J NMO-IgG8 (all AQP4
antibody-positive NMO patients), J 3 and J 4 (AQP4
antibody-negative NMO patients, [4]) and J 5, J 6, and J
7 (AQP4 antibody negative MS patients, [4]). The use of
the patients´ plasma for this study was approved by
the Ethics Committee of Tohoku University School of
Medicine (No. 2007–327) and the Ethics Committee of
Innsbruck Medical University (No. UN3041, 257/4.8).
Removal of AQP4-specific antibodies from NMO-IgG
preparations
NMO-IgG of 2 NMO patients (I GF and J NMO-IgG6)
was depleted of AQP4-specific antibodies as described be-
fore [4]. This led to a drop in AQP4-specific antibody titers
from 1:2560 (untreated NMO-IgG) to 1:1280 (NMO-IgG
absorbed with HEK-EmGFP cells) to 1:320 (NMO-IgG
absorbed with HEK-AQP4/EmGFP cells) for I GF, and
from 1:1280 (untreated NMO-IgG) to 1:640 (NMO-IgG
absorbed with HRK-EmGFP cells) to 1:320 (NMO-IgG
absorbed with HEK-AQP4/EmGFP cells) for NMO-IgG6.
Tissue sampling
The animals were sacrificed by inhalation of an overdose
of CO2. Blood was drawn for the analysis of antibody ti-
ters in the serum. Then, the animals were perfused with
4% paraformaldehyde (PFA), the brains were carefully
dissected, post-fixed for 24 hrs in 4% PFA, and paraffin
embedded.
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2–4 μm thick adjacent serial sections were cut on a micro-
tome. All stainings were done as described before [54],
using the following primary antibodies: polyclonal goat
anti-human IL-1β (1:2000, Santa Cruz Biotechnology,
Heidelberg, Germany), polyclonal rabbit anti-rat AQP4
(1:250, Sigma-Aldrich, Vienna, Austria), biotinylated
sheep anti-human IgG (1:200, Amersham GE Healthcare,
Vienna, Austria), donkey anti-rat IgG (1:1500, Jackson
Immunoresearch, West Grove, PA, USA), rabbit anti-rat
C9neo (1:2000, [55]), rabbit anti-rat C1q (1:100, kindly
provided by Sara Piddlesden), polyclonal rabbit anti-cow
glial fibrillary acidic protein (GFAP, cross-reactive with
rat; 1:3000; DakoCytomation), monoclonal mouse anti-
rat ED1 (1:10000), monoclonal rabbit anti-human CD3
(cross-reactive to rat CD3, 1:2000, Thermo Scientific,
Vienna, Austria), monoclonal mouse anti-rat W3/13 (1:50,
Harlan Sera-Lab), and rabbit anti-Iba1 (1:3000, Wako
Chemicals, Neuss, Germany).
Immunohistochemistry was completed by incubation
with corresponding biotinylated secondary antibodies
(donkey anti-rabbit, 1:2000, sheep anti-mouse, 1:500, both
antibodies from Jackson ImmunoResearch; donkey anti-
sheep/goat, 1:200, Amersham GE Healthcare), followed by
exposure to avidin-peroxidase complex (1:100 in DB/FCS;
Sigma). Enhancement of the CD3 staining was performed
using biotinylated tyramine amplification [56]. Labeling
was visualized with the AEC system (in case of C9neo or
C1q) or with 3,3’ diaminobenzidine-tetra-hydrochloride
(DAB, Sigma) containing 0,01% hydrogen peroxide. All
sections were counterstained with Meyer’s hematoxylin,
dehydrated and mounted in geltol (sections developed
with the AEC system) or Eukitt (Sigma; all other sections).
For conventional staining, the sections were dewaxed in
xylol for 30 min, rehydrated, and stained with hematoxylin/
eosin.
For immunofluorescent stainings, the sections were
heated for 1 hr in a commercial food steamer using 10 mM
EDTA buffer pH 9.0. The sections were then blocked with
DAKO Antibody Diluent (DAKO), and goat polyclonal
anti-IL-1β (1:125, Santa Cruz Biotechnology) and rabbit
anti-Iba1 (1:1500, Wako Chemicals, Neuss, Germany) were
applied in the same solution overnight, at 4°C. This was
followed by incubation with biotin-conjugated donkey anti-
sheep/goat (1:200, Amersham Biosciences), streptavidin-
Cy2 (1:75, Jackson ImmunoResearch) and donkey anti
rabbit-Cy3 (1:100, Jackson ImmunoResearch) in DB/FCS.
Quantitative analysis
All histological measurements and cell counts were
made using standardized microscopic fields defined by
an ocular morphometric grid. To determine the area of
AQP4 loss around the injection site, a final magnifica-
tion of 200 x was used. The grid was positioned over thewidest area of the lesion, perpendicular to the needle
tract. For final calculation, the area of AQP4 loss caused
by wounding (i.e. the needle tract proper) was subtracted
from the total area of AQP4 loss. The number of cells
recruited to the parenchyma adjacent to the needle tract
was also determined at a final magnification of 200 ×. For
quantification of cell numbers in newly formed perivascu-
lar lesions, a final magnification of 400 × was used, and
cross sections of blood vessels were centered in the grid.Endothelial cell cultures
Rat brain endothelial cells of 7-9-week old (adult) or 3-
week old (juvenile) Lewis rats were cultured essentially
as described [57]. To reach high purity of these cultures,
3 μg puromycin (Sigma)/ml culture medium were added
[58] for the first 3 days in culture. Afterwards, the cul-
ture medium was replaced by endothelial cell medium
(PAA) supplemented with 2 ng/ml recombinant human
basic fibroblast growth factor (R&D Systems) and 500
ng/ml hydrocortisone (Sigma).Immunocytochemical characterization of endothelial cells
Immunocytochemical analysis were done as described [54],
using polyclonal rabbit anti-rat zonula occludens 1 (ZO-1,
1:50, Invitrogen by Life Technologies, Vienna, Austria) and
monoclonal mouse anti-rat ICAM-1 (1:200, AbD Serotec,
Kidlington, UK) as primary, and donkey anti-rabbit Cy5
(1:200, Jackson Immunoresearch) or biotinylated donkey
anti-mouse (1:1500, Jackson ImmunoResearch) as se-
condary antibodies, the latter followed by incubation
with DyLight™ 488-conjugated streptavidin (1:75, Jackson
ImmunoResearch).Cultures of astrocytes and microglial cells
These cells were isolated from neonatal Lewis rats and
propagated/purified essentially as described [54].Chemokine/cytokine treatment of cells
5-7-day old primary rat brain endothelial cell cultures
were washed once with PBS and transferred to endothe-
lial medium without supplements. Since this medium
did not contain serum, serum starvation prior to chemo-
kine/cytokine treatment was not necessary. 10 ng/ml of
cytokines/chemokines were added, and the culture was
continued for 12 (antibody array), 22 (gene expression
analysis), or 24 hrs (immunocytochemistry). For anti-
body array analyses, 1 μl of protein transport inhibitor
solution (BD GolgiPlug™, BD Biosciences) was included
in the medium. After cytokine treatment, cells were
washed three times with PBS and subjected either to
RNA or protein isolation, or to immunocytochemical
staining.
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free conditions over night, and were then incubated with
10 ng/ml IL-1β for 22 hrs.Antibody array analysis
Cells were washed with PBS. Proteins were isolated and
analysed using the RayBioW Rat Cytokine Array 2 kit
(RayBiotech, Norcross, GA, USA) according to the man-
ufacturer’s instructions.RNA isolation and cDNA synthesis
RNA was isolated with the RNeasy kit and QIAshredder
(both from Qiagen, Vienna, Austria) according to the in-
structions of the manufacturer. First strand cDNA was
synthesized using M-MLV Reverse Transcriptase (Promega,
Mannheim, Germany), as suggested by the manufacturer.
Afterwards, the cDNA was used directly for polymerase
chain reactions (PCR).PCR analysis
The following primer pairs were used: Cxcl1 (forward 50-
AAGGGTGTCCCCAAGTAATGG-30; reverse 50-CCTT
CTTCCCGCTCAACACC-30), Cxcl2 (forward 50-CAC
CAACCATCAGGGTACAGG-30; reverse 50-GAGGCA
CATCAGGTACGATCC-30), CSF-3 (forward 50-TTGC
CACCACCATCTGGC-30; reverse 50-ACTGCTGTTTA
AATATTAAACAGGG-30), Ccl2 (forward 50-CACTCA
CCTGCTGCTACTCATTCA-30; reverse 50-GCTTGAG
GTGGTTGTGGAAAAG-30), Ccl5 (forward 50-CTGCT
GCTTTGCCTACCTCTCC-30; reverse 50-GATAGCATC
TATGCCCTCCCAGG-30), Icam1 (forward 50- GGGTT
GGAGACTAACTGGATGA-30; reverse 50-GGATCGAG
CTCCACTCGCTC-30), Vcam1 (forward 50-GAGACAA
AACAGAAGTGGAAT-30; reverse 50-AGCAACGTTG
ACATAAAGAGT-30) and GAPDH (forward 50-GGCAT
TGCTCTCAATGACACC-30; reverse 50-TGAGGGTGC
AGCGAACTTTAT-30). The FastStart Taq DNA Poly-
merase kit (Roche Applied Science, Vienna, Austria) was
used for amplifications. One reaction consisted of: 5 μl
10x PCR buffer (200 mMTris–HCl, pH 8.4, 500 mM
KCl), 1 μl 10 mM dNTP mix, 1 μl forward primer (100
pmol/μl), 1 μl reverse primer (100 pmol/μl), 0.4 μl poly-
merase (5 U/μl), 1 μl cDNA and 40.6 μl H2O. The reac-
tion mixture was subjected to an initial denaturation
step (11 min, 95°C), and then to 25, 28, 30 or 35 cycles
of denaturation (30 s, 95°C), annealing (30 s; 55°C for
Cxcl1, 57°C for Cxcl2 and Csf3, 56°C for Ccl2 and
Icam1, 59°C for Ccl5, 49°C for Vcam1, and 53°C for
GAPDH) and elongation (30 s, 72°C). The reaction was
terminated with final extension for 10 min at 72°C, and
PCR products were detected by agarose gel electrophoresis.Statistics
The following statistical evaluations were performed
using the PASW statistics 18 software system (SPSS Inc.,
Chicago, USA): One-way ANOVA, followed by Dunett
T3 post-hoc test, and Kruskal-Wallis followed by Mann–
Whitney U test and Bonferroni-Holm correction.
Additional files
Additional file 1: Loss of AQP4 and neutrophil infiltration in
perivascular areas distant from the needle tract. (a-d) The location of
lesions with AQP4 loss and neutrophil infiltration in IL-1β injected, NMO-
IgG seropositive juvenile (a,c) and adult rats (b,d). The lesions were
observed in the cortex, striatum and thalamus (see boxes in a and b), but
were not observed in the contralateral hemisphere. (c) Cortical lesion
boxed in (a), insert shows neutrophils. (d) thalamic lesion boxed in (b).
(e-f) When IL-1β has been administered to the striatum of animals
carrying human control antibodies instead of NMO-IgG in their serum,
vessels with larger numbers of intraluminal neutrophils were observed,
while there were almost no neutrophils in the surrounding parenchyma.
Tissue sections were stained for AQP4 (brown), and counterstained with
hematoxylin to reveal nuclei (blue). The needle tract is shown by the
dashed line. The black arrows point to neutrophils. Bar = 25 μm.
Additional file 2: Differences in C9neo deposition and astrocyte
loss between lesions. Locations of representative ipsilateral lesions (a, b)
or corresponding contralateral blood vessel (c), of IL-1β-injected animal,
are depicted in schemes. Serial sections of those lesions are shown after
stainings for C9neo (red, d, e, f), human IgG (brown, g, h, i), AQP4 (brown,
j, k, l), GFAP (brown, m, n, o), W3/13 (brown, p, q, r) and ED1 (brown, s, t,
u). The sections were counterstained with hematoxylin to reveal nuclei
(blue), and represent lesions ipsilateral close (a,d,g,j,m,p,s) and distant (b,e,
h,k,n,q,t) to the needle tract, or, for comparison, blood vessels found at
the contralateral side (c,f,i,l,o,r,u,). Note, that lesions closer to the needle
tract are characterized by higher levels of complement deposition, by
more severe astrocytic damage (i.e. loss of GFAP reactivity), and by the
recruitment of more W3/13+ cells (granulocytes and T cells) than their
more distant counterparts. Bar = 25 μm.
Additional file 3: Effects of IL-1β on microglia and astrocytes
in vitro. Microglia and astrocytes were stimulated for 22 hours with IL-1β
or vehicle, and then subjected to PCR analysis of the following genes:
Cxcl1, Cxcl2, Ccl2, Ccl5, Icam1, Vcam1, and GAPDH.
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